GILD
MRK
The once-a-week pitch
Gilead and Merck just put some serious lipstick on the future of HIV care. Their investigational once-weekly oral regimen, ISL/LEN, hit the primary endpoint in two Phase 3 studies and kept viral suppression in check for 48 weeks in adults who switched off daily therapy.
Why this matters
If you’re a patient, fewer pills is obviously nice. If you’re an investor, fewer pills can mean a bigger commercial moat. A once-weekly single-tablet regimen would be a pretty meaningful step away from the current daily grind — and that kind of convenience can matter a lot in chronic disease markets.
The headline stats were solid:
- In ISLEND-1, zero people on weekly ISL/LEN hit 50 copies/mL or higher at Week 48, versus 0.3% on Biktarvy.
- In ISLEND-2, the weekly regimen stayed non-inferior too, with 0.3% versus 1.3% on standard care.
- Side effects were mostly the usual suspects: headache, nausea, and some diarrhea. Discontinuations stayed low.
The stock-angle fine print
The data are clearly a win for the science story, but markets don’t always applaud at the same volume as clinical conferences. Gilead shares were actually down while Merck was up a bit, which is peak “good news, complicated tape” behavior.
Still, the bigger story is the regulatory path. The companies said these results will support planned submissions, and that means the real sequel is whether regulators buy the weekly-dosing vision.
Big picture: if this turns into an approved product, it could nudge HIV treatment from a daily chore into a weekly habit — and that’s a much easier pitch to patients, doctors, and maybe Wall Street too.